Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0014070 (
encephalomyelitis
)
13,017
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tetraspanins are a conserved family of proteins involved in a number of biological processes including, cell-cell interactions, fertility, cancer metastasis and immune responses. It has previously been shown that
TSPAN32
knockout mice have normal hemopoiesis and B-cell responses, but hyperproliferative T cells. Here, we show that
TSPAN32
is expressed at higher levels in the lymphoid lineage as compared to myeloid cells. In vitro activation of T helper cells via anti-CD3/CD28 is associated with a significant downregulation of
TSPAN32
. Interestingly, engagement of CD3 is sufficient to modulate
TSPAN32
expression, and its effect is potentiated by costimulation with anti-CD28, but not anti-CTLA4, -ICOS nor -PD1. Accordingly, we measured the transcriptomic levels of
TSPAN32
in polarized T cells under Th1 and Th2 conditions and
TSPAN32
resulted significantly reduced as compared with unstimulated cells. On the other hand, in Treg cells,
TSPAN32
underwent minor changes upon activation. The in vitro data were finally translated into the context of multiple sclerosis (MS). Encephalitogenic T cells from Myelin Oligodendrocyte Glycoprotein (MOG)-Induced Experimental Autoimmune
Encephalomyelitis
(EAE) mice showed significantly lower levels of
TSPAN32
and increased levels of CD9, CD53, CD82 and CD151. Similarly, in vitro-activated circulating CD4 T cells from MS patients showed lower levels of
TSPAN32
as compared with cells from healthy donors. Overall, these data suggest an immunoregulatory role for
TSPAN32
in T helper immune response and may represent a target of future immunoregulatory therapies for T cell-mediated autoimmune diseases.
...
PMID:Modulation of Tetraspanin 32 (TSPAN32) Expression in T Cell-Mediated Immune Responses and in Multiple Sclerosis. 3148 88